NICE changes stance on Keytruda for first-line head and neck...

As recently as June, NICE was minded not to back routine NHS of MSD’s Keytruda as a first-line treatment for advanced head and n

Merck, Pfizer’s Bavencio flunks head and neck cancer trial

NICE rejects Astellas' Xospata in AML, queries MSD's Keytrud...

NICE has been busy with announcements today, rejecting Astellas’ Xospata for a certain type of acute myeloid leukaemia (AML) and querying evidence for MSD's Keytruda in head and neck cancer

Transgene starts trials of ‘digital’ cancer vaccine with NEC

Transgene begins trials of head and neck cancer vaccine

Virus-based immunotherapy biotech Transgene is to begin clinical trials of its head and neck cancer drug candidate TG4050 after gaining regulatory clearance from the UK regulator.<

Merck claims a brace of head and neck cancer approvals

Merck & Co/MSD has done the double in head and neck cancer with a pair of FDA approvals for Keytruda in newly diagnosed patients on the same day.